Ladenburg Thalmann Financial Services’s Heron Therapeutics HRTX Stock Holding History

Ladenburg Thalmann Financial Services’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$60K	Buy	2,579 +1,862	+260%	+$41.2K	﹤0.01%	3387
2019 Q3	$13K	Buy	717 +357	+99%	+$6.57K	﹤0.01%	4261
2019 Q2	$6K	Sell	360 -622	-63%	-$12.4K	﹤0.01%	4639
2019 Q1	$23K	Buy	982 +628	+177%	+$16.4K	﹤0.01%	3910
2018 Q4	$9K	Sell	354 -127	-26%	-$3.49K	﹤0.01%	4336
2018 Q3	$15K	Sell	481 -211	-30%	-$7.86K	﹤0.01%	4064
2018 Q2	$19K	Hold	692	–	–	﹤0.01%	3855
2018 Q1	$19K	Sell	692 -3,345	-83%	-$75.9K	﹤0.01%	3855
2017 Q4	$73K	Hold	4,037	–	–	﹤0.01%	2957
2017 Q3	$65K	Hold	4,037	–	–	﹤0.01%	2911
2017 Q2	$56K	Buy	4,037 +37	+0.9%	+$536	﹤0.01%	2942
2017 Q1	$60K	Buy	4,000 +3,500	+700%	+$48.4K	﹤0.01%	2779
2016 Q4	$7K	Sell	500 -500	-50%	-$7.84K	﹤0.01%	4071
2016 Q3	$17K	Buy	1,000 +500	+100%	+$9.28K	﹤0.01%	3496
2016 Q2	$9K	Hold	500	–	–	﹤0.01%	3835
2016 Q1	$9K	Hold	500	–	–	﹤0.01%	3757
2015 Q4	$13K	Hold	500	–	–	﹤0.01%	3515
2015 Q3	$12K	Hold	500	–	–	﹤0.01%	3416
2015 Q2	$16K	Buy	+500	New	+$9.41K	﹤0.01%	3382

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Ladenburg Thalmann Financial Services's HRTX Position: Q4 2019 in Review

Ladenburg Thalmann Financial Services increased its Heron Therapeutics (HRTX) stake by 260% in Q4 2019, buying an estimated $41.2K and bringing the position to 2,579 shares worth $60K. The position accounts for ﹤0.01% of the portfolio, ranked #3387.

Ladenburg Thalmann Financial Services first reported a position in HRTX in Q2 2015 and has held it in 19 quarters since. The position peaked at $73K in Q4 2017. 199 funds tracked by Wall St. Rank hold HRTX as of Q4 2019.

Ladenburg Thalmann Financial Services held 2,579 shares of Heron Therapeutics worth $60K as of Q4 2019.
Ladenburg Thalmann Financial Services bought 1,862 Heron Therapeutics shares in Q4 2019, an estimated $41.2K.
Heron Therapeutics made up ﹤0.01% of Ladenburg Thalmann Financial Services's portfolio in Q4 2019, its #3387 holding.
Ladenburg Thalmann Financial Services first reported a position in Heron Therapeutics in Q2 2015 and has held it in 19 quarters since.
Ladenburg Thalmann Financial Services's Heron Therapeutics position peaked at $73K in Q4 2017.
199 funds tracked by Wall St. Rank held Heron Therapeutics as of Q4 2019.

Based on Ladenburg Thalmann Financial Services's 13F filing for Q4 2019, filed 14 Feb 2020.